Study identifier:4522US/0003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 12-week, Randomized, Open-Label, 3 Arm Parallel group, Multicenter, Phase IIIb Study comparing the efficacy and safety of Rosuvastatin with Atorvastatin and Simvastatin Achieving NCEP ATP III LDL-C Goals in high risk subjects with Hypercholesterolaemia in the Managed Care Setting.
Hypercholesterolemia
Phase 3
No
Rosuvastatin, Simvastatin, Atorvastatin
All
4444
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to compare the efficacy and safety of rosuvastatin with simvastatin and atorvastatin in reducing levels of low density lipoprotein cholesterol in subjects with hypercholesterolaemia
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 Rosuvastatin | - |
Active Comparator: 2 Simvastatin | - |
Active Comparator: 3 Atorvastatin | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.